摘要
在西方国家,前列腺癌是最主要的男性癌症,它也是人类第二大致命性癌症。虽然大多数前列腺癌患者目前接受手术和/或放射治疗,超过30-40%的患者最终将发展为晚期疾病。到目前为止,治疗方案取决于患者的临床阶段和病理诊断,不幸的是病理诊断往往不能预测真实的预后。目前的治疗方法在治疗转移性疾病方面效果不明显。为了明确诊断和随访,我们需要有助于预测患者的预后的分子标志物。癌症基因组学的进展已经导致了大量的生物标志物,它必须在临床上必须经过严格的验证。癌症基因组学的进展已经发现了大量的生物标志物,但它们必须在临床上经过严格的验证。最近的前列腺癌生物学研究揭示了导致该肿瘤的生物机制,并成功找到了治疗方案。免疫治疗剂、选择性肾上腺抑制剂、抗血管生成的分子、新设计的雄激素受体抑制剂,靶向骨微环境的化合物能通过阻断特定的信号转导通路限制肿瘤的生长。这些方法可以补充现有的治疗模式,提高治疗效果。此外,其他新兴的药理化合物已经表现出良好的结果,一些临床试验正在进行中。本文总结了治疗前列腺癌靶向治疗,并讨论其治疗去势难治性的潜在优点。
关键词: 格里森评分,免疫治疗,单克隆抗体,预后因子,前列腺癌,靶向治疗。
Current Drug Targets
Title:Emerging Targets For Prostate Adenocarcinoma Therapy: How Molecular Biology May Drive Towards a More Tailored Approach
Volume: 17 Issue: 3
Author(s): Maria Raffaella Ambrosio, Luigi Pirtoli and Maria Teresa del Vecchio
Affiliation:
关键词: 格里森评分,免疫治疗,单克隆抗体,预后因子,前列腺癌,靶向治疗。
摘要: Prostate adenocarcinoma is the most diagnosed male cancer in the Western world and the second leading cause of cancer-related mortality. Albeit most of the patients with prostate adenocarcinoma are currently treated by surgery and/or radiation therapy, more than 30-40% of affected subjects will eventually progress and develop advanced disease. To date, management decisions depend on the clinical stage of the patient and the histological diagnosis which unfortunately often lack to predict the real prognosis. Current therapies have shown to be insufficient, mainly in the metastatic disease. For clear-cut diagnosis and follow-up, we promptly need molecular markers also useful in predicting patient's outcome. Advances in cancer genomics have led to a plethora of biomarkers, which must now to be rigorously validated in the clinical setting. Recent insights on prostate adenocarcinoma biology which unveiled some of the biological mechanisms leading to this tumour, have managed in devising novel strategies for therapy. Immunotherapeutic agents, selective adrenal inhibitors, anti-angiogenic molecules, newly engineered androgen receptor inhibitors, compounds targeting the bone microenvironment are demonstrated to limit cancer growth by blocking specific signaling pathways. Such strategies can be complemented to existing therapeutic paradigm in improving beneficial outcome. Moreover, other emerging pharmacological compounds have shown encouraging results and several clinical trials are ongoing. This review summarizes the developing targeted therapies for prostate adenocarcinoma and discuss their potential benefit mainly in the castration- resistant forms.
Export Options
About this article
Cite this article as:
Maria Raffaella Ambrosio, Luigi Pirtoli and Maria Teresa del Vecchio , Emerging Targets For Prostate Adenocarcinoma Therapy: How Molecular Biology May Drive Towards a More Tailored Approach, Current Drug Targets 2016; 17 (3) . https://dx.doi.org/10.2174/1389450116666151019102220
DOI https://dx.doi.org/10.2174/1389450116666151019102220 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Administration of Drug and Nutritional Components in Nano-Engineered Form to Increase Delivery Ratio and Reduce Current Inefficient Practice
Recent Patents on Drug Delivery & Formulation Survey of Recent Literature Related to the Biologically Active 4(3H)-Quinazolinones Containing Fused Heterocycles
Current Medicinal Chemistry Studies on Efficacy of a Novel 177Lu-Labeled Porphyrin Derivative in Regression of Tumors in Mouse Model
Current Radiopharmaceuticals Discovery of a Small Molecule Inhibitor of the Interaction Between HIV-1 Proteins and Cellular Cofactors: A Novel Candidate Anti-HIV-1 Drug
Current Chemical Biology “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Drug Delivery Letters Dynamics of Virus-Host Interplay in HIV-1 Replication
Current HIV Research Targeted Inhibition of Angiogenic Factors in AIDS-related Disorders
Current Drug Targets - Infectious Disorders SRLVs: A Genetic Continuum of Lentiviral Species in Sheep and Goats with Cumulative Evidence of Cross Species Transmission
Current HIV Research Recent Developments in Pleuromutilin Derivatives: A Promising Class Against Bacterial Respiratory Disease
Current Respiratory Medicine Reviews VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy Synthesis of Novel Test Compounds for Antiviral Chemotherapy of Severe Acute Respiratory Syndrome (SARS)
Current Medicinal Chemistry Titanocene Y - Transport and Targeting of an Anticancer Drug Candidate
Letters in Drug Design & Discovery Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors
Current Topics in Medicinal Chemistry Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus- Host Disease After Allogeneic Hematopoietic Cell Transplantation
Current Stem Cell Research & Therapy The Novel VEGF<sub>121</sub>-VEGF<sub>165</sub> Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF<sub>165</sub>/Lon Signaling Through PI3K-AKT-mTOR Pathway
Current Cancer Drug Targets The p53-p66Shc Apoptotic Pathway is Dispensable for Tumor Suppression whereas the p66Shc-generated Oxidative Stress Initiates Tumorigenesis
Current Pharmaceutical Design Preface
Current Drug Targets - Infectious Disorders Invasive Pulmonary Aspergillosis in Acute Leukemia: Current Issues for Pathogenesis, Diagnosis and Treatment
Current Respiratory Medicine Reviews